Видео с ютуба Fda Cber

FDA Direct: Catching Up on Agency Reforms

FDA-NIH 2024 | D1S10 - CBER’s CMC Considerations for Early Phase Studies of Cell and Gene Therapy...

FDA Basics - CBER - Mini-Sentinel/Sentinel Activities Including Prism and Bloodscan

FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

Efficient Communication Reduces Regulatory Uncertainty — CBER Director, US FDA

OTP Town Hall: Gene Therapy Manufacturing CMC & Facility Readiness for BLAs & Post-licensure Changes

What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago

REdI Annual Conference 2024: CBER (Biologics) Innovation in Medical Product Development (Day 1 of 2)

Experiencing the FDA CBER - PHUSE EU Connect 2023

FDA Roundtable on Cell and Gene Therapy

FDA Guidance for Cell and Gene Therapy: Insights from Peter Marks at CGT Summit 2023

Cell & Gene Therapy Products 2022 Keynote: Peter Marks, CBER, FDA

Director of FDA's CBER, Peter Marks, M.D., Ph.D. on COVID-19 Vaccine Confidence

FDA-NIH 2024 | D1S08 - CBER’s Manufacturers Assistance and Technical Training Branch (MATTB)...

Preview: CBER Director Peter Marks Discusses FDA's Credibility at ARM's 2020 Meeting on the Mesa

FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...

FDA Regulatory Education for Industry (REdI) Annual Conference 2023 – Biologics Day 2

Keeping Pace with CGT, Dr Peter Marks, Director CBER, FDA

FDA-NIH 2024 | D1S09 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP

The More Data We Have, the Better - CBER Director, US FDA